Petros Pharmaceuticals, Inc. 8-K

What Happened Petros Pharmaceuticals, Inc. announced on June 18, 2026 that Mitchell Arnold, who served as the Company’s Vice President of Finance, Principal Accounting Officer and Principal Financial Officer, and the Company mutually agreed to his separation effective June 18, 2026. The separation is documented in a General Release and Severance Agreement dated June 18, 2026.

Key Details

• Severance pay: $38,500 (equal to two months of base salary), paid in equal installments per the Company’s standard payroll practices; first installment after the 8th day following Arnold’s execution of the agreement.
• Equity acceleration: 3,000 unvested shares under the February 19, 2025 Restricted Stock Award Agreement were accelerated as of the Separation Date.
• Tax and benefits: Company will pay a lump-sum $100 for estimated taxes related to the equity vesting, and will subsidize COBRA premiums for up to two months (terminates earlier if Arnold gets other group coverage).
• Release and timing: Arnold agreed to waive employment-related claims in exchange for the consideration; he has 21 days to review and a 7-day revocation period after signing, with the agreement becoming enforceable on the 8th day if not revoked.

Why It Matters A departure of the Company’s Principal Accounting Officer and Principal Financial Officer is a material leadership change that investors should note because it affects who signs and oversees financial reporting. The direct cash cost to the company appears modest (two months’ pay plus short COBRA subsidy), and the filing does not name a replacement. Investors should watch for subsequent filings (future 8-Ks or proxy statements) announcing a successor or interim arrangements for financial reporting responsibilities.